Knowledge on Hydroxychloroquine Prescription and Attitude toward its use in COVID-19 - A Survey-Based Study among Doctors

被引:1
作者
Afra, T. P. [1 ]
Uvais, N. A. [2 ]
Bishnoi, Anuradha [5 ]
Sukesh, Edavalath [3 ]
Eliyas, Salin [4 ]
Hafi, N. A. Bishurul [1 ]
Razmi, Muhammed T. [1 ]
机构
[1] IQRAA Int Hosp & Res Ctr, Dept Dermatol, Calicut, Kerala, India
[2] IQRAA Int Hosp & Res Ctr, Dept Psychiat, Calicut, Kerala, India
[3] IQRAA Int Hosp & Res Ctr, Dept Rheumatol, Calicut, Kerala, India
[4] Dept Hlth & Family Welf, Calicut, Kerala, India
[5] Postgrad Inst Med Educ & Res, Dept Dermatol Venereol & Leprol, Chandigarh, India
关键词
Attitude; COVID-19; doctors; hydroxychloroquine; knowledge; physician; survey; CHLOROQUINE;
D O I
10.4103/injr.injr_184_20
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The use of hydroxychloroquine (HCQ) in COVID-19 had garnered enormous media attention. There were conflicting reports as well as unscientific opinion pieces in the scientific literature also. This study was planned to assess the knowledge, attitude, and practice of health-care professionals regarding HCQ. Methods: An online survey was created with 8 knowledge-based questions (n = 2 fact-based [each scoring 1], n = 6 guideline-based [each scoring 2]), and 6 attitude-based questions, and distribution among a target population of doctors was done using GoogleT forms. Results: Of 115 respondents, the majority considered HCQ a safe drug (86.1%) and were in favor of its usage in COVID-19 trials (81.7%) or health-care/contact prophylaxis (60.9%) but against its use as a mass prophylactic agent (80.9%). Contrary to the published guidelines/recommendations, 80% and 55.7% of respondents opined for routine cardiac and glucose-6-phosphate dehydrogenase evaluations before prescribing HCQ. Those who were dealing with COVID-19 patients directly (n = 41) had significantly lower knowledge score compared to the others (6.37 vs. 7.72, P = 0.007). They had significantly lesser awareness for the baseline tests recommended (97.6% vs. 77.0%, P = 0.003). A significantly higher number of these physicians opposed the use of HCQ in clinical trials (26.82% vs. 8.1%, P = 0.027) and health-care/contact prophylaxis (41.5% vs. 16.2%, P = 0.008). Conclusion: Sparse and speedily gathered information on HCQ can influence the practicing doctors, especially those involved directly in COVID-19 patient care, but less familiar with the prescription of this time-tested drug. Possibly, this has a bearing on the counseling of the patients requiring HCQ for non-COVID-19 indications and formulation of new guidelines.
引用
收藏
页码:194 / 199
页数:6
相关论文
共 18 条
[1]   Hydroxychloroquine use in COVID-19: what is the basis for baseline tests? [J].
Afra, T. P. ;
Razmi, Muhammed T. ;
Bishnoi, Anuradha ;
Hafi, N. A. Bishurul .
LANCET INFECTIOUS DISEASES, 2020, 20 (10) :1120-1121
[2]   Doubtful precipitation of hemolysis by hydroxychloroquine in glucose-6-phosphate dehydrogenase-deficient patient with COVID-19 infection [J].
Afra, T. P. ;
Vasudevan Nampoothiri, Ram ;
Razmi, Muhammed T. .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (04) :512-513
[3]   Does hydroxychloroquine combat COVID-19? A timeline of evidence [J].
Alia, Erisa ;
Grant-Kels, Jane M. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (01) :E33-E34
[4]   COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency [J].
Beauverd, Yan ;
Adam, Yannick ;
Assouline, Benjamin ;
Samii, Kaveh .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (03) :357-359
[5]  
CDC Health Alert Network, 2019, SEV ILLN ASS US NONP
[6]   The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis [J].
Commons, Robert J. ;
Simpson, Julie A. ;
Thriemer, Kamala ;
Chu, Cindy S. ;
Douglas, Nicholas M. ;
Abreha, Tesfay ;
Alemu, Sisay G. ;
Anez, Arletta ;
Anstey, Nicholas M. ;
Aseffa, Abraham ;
Assefa, Ashenafi ;
Awab, Ghulam R. ;
Baird, J. Kevin ;
Barber, Bridget E. ;
Borghini-Fuhrer, Isabelle ;
D'Alessandro, Umberto ;
Dahal, Prabin ;
Daher, Andre ;
de Vries, Peter J. ;
Erhart, Annette ;
Gomes, Margarete S. M. ;
Grigg, Matthew J. ;
Hwang, Jimee ;
Kager, Piet A. ;
Ketema, Tsige ;
Khan, Wasif A. ;
Lacerda, Marcus V. G. ;
Leslie, Toby ;
Ley, Benedikt ;
Lidia, Kartini ;
Monteiro, Wuelton M. ;
Pereira, Dhelio B. ;
Phan, Giao T. ;
Phyo, Aung P. ;
Rowland, Mark ;
Saravu, Kavitha ;
Sibley, Carol H. ;
Siqueira, Andre M. ;
Stepniewska, Kasia ;
Taylor, Walter R. J. ;
Thwaites, Guy ;
Tran, Binh Q. ;
Hien, Tran T. ;
Vieira, Jose Luiz F. ;
Wangchuk, Sonam ;
Watson, James ;
William, Timothy ;
Woodrow, Charles J. ;
Nosten, Francois ;
Guerin, Philippe J. .
BMC MEDICINE, 2019, 17 (1)
[7]   Urgent Guidance for Navigating and Circumventing the QTc-Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for Coronavirus Disease 19 (COVID-19) [J].
Giudicessi, John R. ;
Noseworthy, Peter A. ;
Friedman, Paul A. ;
Ackerman, Michael J. .
MAYO CLINIC PROCEEDINGS, 2020, 95 (06) :1213-1221
[8]   The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs: a systematic review [J].
Haeusler, Ilsa L. ;
Chan, Xin Hui S. ;
Guerin, Philippe J. ;
White, Nicholas J. .
BMC MEDICINE, 2018, 16
[9]   G6PD and chloroquine: Selecting the treatment against SARS-CoV-2? [J].
Kassi, Eva N. ;
Papavassiliou, Kostas A. ;
Papavassiliou, Athanasios G. .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2020, 24 (09) :4913-4914
[10]   Chloroquine and hydroxychloroquine are associated with reduced cardiovascular risk: a systematic review and meta-analysis [J].
Liu, Dan ;
Li, Xiaodan ;
Zhang, Yonggang ;
Kwong, Joey Sum-Wing ;
Li, Ling ;
Zhang, Yiyi ;
Xu, Chang ;
Li, Qianrui ;
Sun, Xin ;
Tian, Haoming ;
Li, Sheyu .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 :1685-1695